Agent for preventing or treating organ functional disorders and organ dysfunction

a functional disorder and organ technology, applied in the field of agents for preventing, treating or suppressing the progress of organ functional disorders and organ dysfunction, can solve the problems of low clinical effect of ubiquinone per se, unclear clinical availability, and general difficulty in ubiquinone migration to organs

Inactive Publication Date: 2006-10-26
SUGIYAMA YASUO +2
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008] The present inventors have conducted intensive studies and found, for the first time, that a compound having a squalene synthase inhibitory effect is sufficiently clinically useful as a medicament having an effect for treating or preventing organ functional disorders and organ dysfunction due to arteriosclerotic diseases (specifically ischemic heart diseases) or cerebrovascular disease (specifically cerebral infarction, encephalorrhagy), etc., an effect for suppressing of progress, and an effect of life-lengthening, etc., based on the ubiquinone increasing effect, which results in the completion of the present study.
[0494] In addition, since the SSI compound shows blood glucose lowering effect in a rat suffering from endomorph diabetes mellitus, the compound improves insulin resistance. The agent is, in view of its biological characteristics, especially suitable for the prevention or treatment of hyperglycemia and deuteropathy arising therefrom such as complications observed in diabetic nephropathy and renal failure, cardiovascular diseases, such as anaemia, metabolic bone disorder, vomition, nausea, asitia, diarrhea, etc., nervous symptoms such as diphtheritic neuropathy, etc., diabetic neuropathy, diabetic retinopathy, diabetic vascular disorder, as well as insulin resistance and diseases arising therefrom such as hypertension, impaired glucose tolerance and deuteropathy such as cardiac disease, cerebral ischemia, claudicatio intermittens, gangraena, etc.

Problems solved by technology

However, it has been known that ubiquinone is generally difficult to migrate to organs, and that the clinical effect of administration of ubiquinone per se is not high (Life Science, Vol. 64, No. 5, pp.
However, the clinical availability is still not clear.
However, it has been also known to not increase peroxisome in human, and therefore the clinical availability is still not clear.
Therefore, under the present circumstances, a useful therapeutic drug that increases ubiquinone to treat or prevent organ functional disorders and organ dysfunction is not available.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Agent for preventing or treating organ functional disorders and organ dysfunction
  • Agent for preventing or treating organ functional disorders and organ dysfunction
  • Agent for preventing or treating organ functional disorders and organ dysfunction

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0539] According to the following composition, a mixture consisting of compound A (175 g), D-mannitol (175 g), corn starch (118.65 g) and crosscarmelose sodium (105 g) is sufficiently mixed using a vertical granulator (FM-VG-10 type, manufactured by Powrex Corporation), and kneaded with an aqueous solution in which hydroxypropyl cellulose (19.25 g) has been dissolved (condition for kneeding: 400 rpm, 10 min). The white-colored kneaded substance is dried using a fluidized drier (FD-3S, manufactured by Powrex Corporation) under the blow temperature of 60° C. for 30 min, and granulated by, using a power mill (model P-3, manufactured by Showa Chemical Machinery Co., Ltd.) and sieving with a 1.5 mmφ punching screen.

[0540] The granule (525.14 g), crosscarmelose sodium (31 g) and magnesium stearate (1.86 g) are added and mixed using a mixer (model TM-15, manufactured by Showa Chemical Machinery Co., Ltd.) for 5 min to give granule for tabletting. The granule is formed, using a tablet form...

preparation example 2

[Preparation of Coating Agent]

[0543] Hydroxypropylmethyl cellulose 2910 (TC-5) (224.4 g) and Macrogol 6000 (45.0 g) were dissolved in purified water (2700 g). To the obtained solution were dispersed titanium oxide (30.0 g) and red iron oxide (0.6 g) to prepare a coating agent.

[Preparation of Tablets]

[0544] Compound A (31.0 g), lactose (3053.5 g) and corn starch (930.0 g) were homogeneously mixed in a fluidized bed granulation dryer (FD-5S, manufactured by Powrex Corporation), and an aqueous solution in which hydroxypropyl cellulose (HPC-L, 139.5 g) had been dissolved was sprayed to perform granulation in the apparatus, then the granule was dried in a fluidized bed granulation dryer.

[0545] The obtained granulated product was crushed by 1.5 mm punching screen using Power Mill grinder (P-3, manufactured by Showa Chemical Machinery Co., Ltd.) to give sized powder.

[0546] To the obtained sized powder (3430 g) were added carmellose calcium (384 g) and magnesium stearate (25.6 g), and ...

preparation example 3

[Preparation of Coating Agent]

[0550] Hydroxypropylmethyl cellulose 2910 (TC-5, 224.4 g) and Macrogol 6000 (45.0 g) were dissolved in purified water (2700 g). To the obtained solution were dispersed titanium oxide (30.0 g) and red iron oxide (0.6 g) to prepare a coating agent.

[Preparation of Tablets]

[0551] Compound A (310.0 g), lactose (2774.5 g) and corn starch (930.0 g) were homogeneously mixed in a fluidized bed granulation dryer (FD-5S, manufactured by Powrex Corporation), and an aqueous solution in which hydroxypropyl cellulose (HPC-L, 139.5 g) had been dissolved was sprayed to perform granulation in the apparatus, then the granule was dried in a fluidized bed granulation dryer.

[0552] The obtained granulated product was crushed by 1.5 mmφ punching screen using Power Mill grinder (P-3, manufactured by Showa Chemical Machinery Co., Ltd.) to give sized powder.

[0553] To the obtained sized powder (3430 g) were added carmellose calcium (384 g) and magnesium stearate (25.6 g), and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
wt %aaaaaaaaaa
mean particle diameteraaaaaaaaaa
mean particle diameteraaaaaaaaaa
Login to view more

Abstract

The present invention provides an agent for preventing or treating organ functional disorders, an agent for preventing or treating organ dysfunction and an agent for preventing or treating obesity and deuteropathy thereof, each of which comprises a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof; as well as a ubiquinone increasing agent comprising a compound having a squalene synthase inhibitory effect or a salt thereof or a prodrug thereof.

Description

TECHNICAL FIELD [0001] The present invention relates to an agent for preventing, treating or suppressing progress of organ functional disorders and organ dysfunction, which comprises a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof; and an agent for preventing, treating or suppressing progress of organ functional disorders and organ dysfunction, which comprises a compound having a squalene synthase inhibitory effect or a salt thereof or a prodrug thereof; as well as an agent for increasing ubiquinone, which comprises a compound having a squalene synthase inhibitory effect or a salt thereof or a prodrug thereof, etc. [0002] Furthermore, the present invention relates to an agent for maintaining organ function, an agent for protecting organs, an agent for suppressing organ cell death, etc., each of which comprises a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof, etc. BACKGROUND ART [0003] Ubiquinone ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/553A61P1/18A61P3/04A61P3/06A61P3/10A61P9/06A61P9/10A61P9/12A61P9/14A61P13/02A61P13/12A61P25/16A61P25/28A61P43/00C07D267/14C07D281/10C07D413/04C07D413/06C07D413/12C07D417/04
CPCA61K31/553C07D267/14C07D281/10C07D417/04C07D413/06C07D413/12C07D413/04A61P1/18A61P13/02A61P13/12A61P25/16A61P25/28A61P3/10A61P3/04A61P3/06A61P43/00A61P9/06A61P9/10A61P9/12A61P9/14
Inventor SUGIYAMA, YASUONISHIMOTO, TOMOYUKIKIYOTA, YOSHIHIRO
Owner SUGIYAMA YASUO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap